Sequential treatment of actinic keratosis with cryotherapy and ingenol mebutate: reflectance confocal microscopy monitoring of efficacy and local skin reaction

2018 ◽  
Vol 57 (10) ◽  
pp. 1178-1181 ◽  
Author(s):  
Paola Pasquali ◽  
Gonzalo Segurado-Miravalles ◽  
Salvador González
Keyword(s):  
Confocal Microscopy ◽  
Skin Reaction ◽  
Actinic Keratosis ◽  
Sequential Treatment ◽  
Reflectance Confocal Microscopy ◽  
Ingenol Mebutate ◽  
Local Skin ◽  
Local Skin Reaction

scholarly journals Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel: Report of Two Cases

2016 ◽  
Vol 6 (1) ◽  
pp. 81-87 ◽  
Author(s):  
Caterina Longo ◽  
Stefania Borsari ◽  
Elisa Benati ◽  
Elvira Moscarella ◽  
Roberto Alfano ◽  
...  
Keyword(s):  
Confocal Microscopy ◽  
Actinic Keratosis ◽  
Reflectance Confocal Microscopy ◽  
Ingenol Mebutate

scholarly journals Severe local skin reaction after the application of ingenol mebutate gel treated by photodynamic therapy: A case report

2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Luca Negosanti ◽  
Rossella Sgarzani ◽  
Matteo Santoli ◽  
Massimino Negosanti ◽  
Nicoletta Banzola ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Actinic Keratosis ◽  
Aminolevulinic Acid ◽  
Severe Side Effect ◽  
Severe Reaction ◽  
Ingenol Mebutate ◽  
Local Skin ◽  
Local Skin Reaction ◽  
Patient Reported ◽  
Local Reactions

<p>Ingenol mebutate (IM) was recently introduced for the treatment of actinic keratosis (AK). It is considered a safe and effective treatment in spite of local reactions frequently reported. These reactions may consist of erythema, flaking, crusting, swelling, vesicles and erosions, and would usually spontaneously recede within 20–30 days. We reported a case of a patient affected by multiple actinic keratosis of the scalp treated with IM. The patient reported a severe reaction that was not solved in two months. We decided to treat the reaction with photodynamic therapy and aminolevulinic acid. This treatment was demonstrated to be effective in solving this severe side effect.</p>

scholarly journals Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel

2016 ◽  
Vol Volume 9 ◽  
pp. 211-216 ◽  
Author(s):  
K Neumann ◽  
Shelbi Jim On ◽  
Kim Mark Knudsen ◽  
Torsten Skov ◽  
Mark Lebwohl
Keyword(s):  
Skin Reaction ◽  
Ingenol Mebutate ◽  
Skin Reactions ◽  
Local Skin ◽  
Local Skin Reaction

Post-marketing safety surveillance of tumor treating fields (TTFields) in patients with high-grade glioma in clinical practice.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 2542-2542
Author(s):  
Wenyin Shi ◽  
Deborah T. Blumenthal ◽  
Nancy Ann Oberheim Bush ◽  
Seid Kebir ◽  
Rimas Vincas Lukas ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Brain Tumors ◽  
Elderly Patients ◽  
Skin Reaction ◽  
Anaplastic Astrocytoma ◽  
Phase Iii ◽  
Local Skin ◽  
Tumor Treating Fields ◽  
Safety Surveillance ◽  
Local Skin Reaction

2542 Background: Tumor Treating Fields (TTFields) are an antineoplastic treatment delivering low intensity, intermediate frequency, alternating electric fields through two pairs of transducer arrays locoregionally applied to tumor bed. TTFields are FDA-approved for glioblastoma (GBM; 200 kHz) and mesothelioma (150 kHz). Safety and effectiveness were demonstrated in the phase III EF-11 and EF-14 trials in recurrent GBM (rGBM) and in newly diagnosed GBM (ndGBM), respectively. The main TTFields-related adverse event (AE) was array-associated manageable skin irritation. We report AEs from TTFields-treated patients in the real-world, clinical practice setting. Methods: Unsolicited, global, post-market surveillance data from TTFields-treated patients (October 2011–February 2019) were retrospectively analyzed using MedDRA v21.1, stratified by region (US, EMEA [Europe, Middle East, Africa], or Japan), diagnosis (ndGBM, rGBM, anaplastic astrocytoma and anaplastic oligodendroglioma, or other brain tumors that includes brain metastases from different cancer types), and years of age (<18, pediatric; 18 to 64, adults; or ≥65, elderly). Results: Of 11,029 patients, 53% had ndGBM, 39% had rGBM (at any line of recurrence), 6% had anaplastic astrocytoma/oligodendroglioma, and 1% had other brain tumors. Most were adults (73%) and 26% were elderly (≥65 years of age). The majority of patients were males (66.3%) compared to females (33.7%), with a ratio representative of a typical GBM population. The most reported TTFields-related AE was array-associated local skin reaction, with an incidence of 38% in ndGBM, 29% in rGBM, 38% in anaplastic astrocytoma/oligodendroglioma, 31% in other brain tumors, 37% in pediatric, 34% in adults, and 36% in elderly patients. Most skin AEs were mild to moderate and resolved with no treatment or over the counter topical ointments. Incidence of other TTFields-related AEs in patients with ndGBM and rGBM, respectively, included heat sensation (under-array warmth; 11%, 10%), electric sensation (under-array tingling; 11%, 9%), and headache (7%, 6%). Conclusions: This retrospective, global, TTFields safety surveillance analysis revealed no new safety signals, with favorable safety and tolerability comparable to published TTFields/GBM trials. The most common TTFields-related AE was array-associated local skin reaction. The safety profile remained consistent among subgroups (diagnosis, age, or region) and total cohort, indicating feasibility in multiple subpopulations, including elderly patients.

Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases

2014 ◽  
Vol 30 (2) ◽  
pp. 320-321 ◽  
Author(s):  
C. Longo ◽  
L. Neri ◽  
G. Argenziano ◽  
S. Calvieri ◽  
P.G. Calzavara-Pinton ◽  
...  
Keyword(s):  
Actinic Keratosis ◽  
Ingenol Mebutate ◽  
Skin Reactions ◽  
Local Skin
Sign in / Sign up

Export Citation Format

Share Document